Stockscreener 앱 받기
6.34
4.80%
-0.32
시간 외 거래:
6.40
0.06
+0.95%
전일 마감가:
$6.66
열려 있는:
$6.67
하루 거래량:
11.32M
Relative Volume:
2.32
시가총액:
$1.65B
수익:
$6.28B
순이익/손실:
$700.00M
주가수익비율:
2.355
EPS:
2.6922
순현금흐름:
$537.00M
1주 성능:
-29.08%
1개월 성능:
-38.74%
6개월 성능:
-51.82%
1년 성능:
-64.48%
1일 변동 폭
$6.32
$6.84
1주일 범위
$6.32
$9.28
52주 변동 폭
$6.32
$19.05
오가논 & Co Stock (OGN) Company Profile
명칭
Organon Co
전화
551-430-6000
주소
30 HUDSON STREET, JERSEY CITY
OGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
6.34 | 1.73B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
813.53 | 735.18B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
186.60 | 450.37B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
225.14 | 401.96B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
121.80 | 238.94B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
86.58 | 217.38B | 63.43B | 16.42B | 14.72B | 6.4861 |
오가논 & Co Stock (OGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-27 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-09-06 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-11-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-09-21 | 개시 | Barclays | Overweight |
| 2023-03-16 | 개시 | Raymond James | Outperform |
| 2022-10-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 개시 | Piper Sandler | Neutral |
| 2021-09-01 | 개시 | BofA Securities | Buy |
| 2021-07-22 | 개시 | Citigroup | Buy |
| 2021-06-15 | 개시 | JP Morgan | Neutral |
| 2021-06-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 개시 | Evercore ISI | Outperform |
모두보기
오가논 & Co 주식(OGN)의 최신 뉴스
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - GlobeNewswire Inc.
Organon: Critical Assessment Of The Audit Committee Investigation Results (NYSE:OGN) - Seeking Alpha
Organon & Co. (NYSE:OGN) Shares Down 6.2% Following Analyst Downgrade - MarketBeat
Organon Looks For New CEO Amid Investigation Into Front-Loading Contraceptive Implant Sales - Citeline News & Insights
Organon (OGN) Is Down 26.2% After CEO Resignation and Audit Reveals Sales Practice Issues – What's Changed - simplywall.st
Peregrine Capital Management LLC Increases Stock Position in Organon & Co. $OGN - MarketBeat
Why Organon (OGN) Stock Is Down Today - TradingView
Organon’s Stock Tumbles Amidst Leadership Shake-Up - StocksToTrade
Organon hit hard over ousted CEO scandal - The Pharma Letter
The Bottom Fishing ClubOrganon: Deep Value In Drugs/Medical Products (NYSE:OGN) - Seeking Alpha
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co.OGN - FinancialContent
Organon Investor Alert: CEO Resigns Amid Audit ProbeSecurities Fraud Investigation on Behalf of Organon InvestorsContact Kehoe Law Firm, P.C.OGN - ACCESS Newswire
Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $10 - 富途牛牛
Organon’s Stock Sinks, But Deep Value Beckons For Patient Investors - Finimize
Organon & Co stock hits 52-week low at 7.26 USD - Investing.com Australia
Organon makes personnel moves after internal probe finds ‘improper’ sales practices - ROI-NJ
Organon appoints interim CEO amid sales practice investigation By Investing.com - Investing.com Canada
Organon & Co.’s Promising Phase 3 Study on Tapinarof Cream for Pediatric Plaque Psoriasis - TipRanks
Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper - GlobeNewswire
Kaplan Fox is Investigating Organon & Co. (OGN) Following an Announcement of Findings of an Audit Committee Investigation and CEO Resignation - NewMediaWire
Organon CEO resigns after probe into 'improper' sales practices - FirstWord Pharma
Biotech Outshines As Healthcare Stocks See Mixed Moves - Finimize
This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 22%. - Barron's
Organon CEO resigns amid Nexplanon sales probe (updated) - NJBIZ
Organon CEO stands down amid contraceptive sales malpractice probe - Yahoo Finance
Stocks making the biggest moves midday: Qualcomm, Fermi, Dyne Therapeutics, Organon, Snowflake and more - CNBC
This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 25%. - Barron's
Piper Sandler Downgrades Organon to Underweight From Overweight, $5 Price Target - MarketScreener
Organon Appoints Interim CEO and Board Chair; Reports Results of Audit Committee Investigation - New Jersey Business Magazine
Organon cut to Underweight at Piper Sandler on internal control concerns - Seeking Alpha
Organon Appoints Company Executive Joseph Morrissey as Interim CEO - citybiz
Organon & Co stock hits 52-week low at 7.26 USD By Investing.com - Investing.com South Africa
Organon CEO Resigns After Probe Finds Improper Sales Practices - Bloomberg.com
Organon appoints company executive Joseph Morrissey as interim CEO and board chair Carrie Cox as executive chair; announces results of audit committee investigation - MarketScreener
Organon Appoints Company Executive Joseph Morrissey As Interim CEO And Board Chair Carrie Cox As Executive Chair Announces Results Of Audit Committee Investigation - TradingView
Organon CEO Kevin Ali to resign after probe into contraceptive sales - Reuters
Organon CEO Kevin Ali Resigns Amid Audit Probe Into Wholesaler Sales Practices - Stocktwits
Organon & Co. Announces CEO Changes - MarketScreener
Organon stock tumbles after CEO resigns amid sales practice investigation By Investing.com - Investing.com UK
Organon falls as CEO resigns after probe into contraceptive sales - TradingView
Organon CEO Kevin Ali to resign after probe into wholesaler sales practices - MarketScreener
Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation - Stock Titan
Co. (7XP) stock considered safe havenMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com
Co. (7XP) stock in 20252025 Big Picture & Capital Efficiency Focused Ideas - newser.com
Organon & Co. (NYSE:OGN) Given Sell (D+) Rating at Weiss Ratings - MarketBeat
Co. (7XP) stock survive global slowdown2025 Sector Review & Safe Entry Point Alerts - newser.com
Assessing Organon Stock After a 39.5% Drop and Recent Portfolio Moves - Yahoo Finance
Organon (OGN) Laps the Stock Market: Here's Why - sharewise.com
Organon (OGN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
Organon & Co. (OGN) Stock Analysis: Exploring a 40.69% Potential Upside Amidst Healthcare Sector Challenges - DirectorsTalk Interviews
오가논 & Co (OGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
0.53%
자본화:
|
볼륨(24시간):